PMID- 31848739
OWN - NLM
STAT- MEDLINE
DCOM- 20201116
LR  - 20220701
IS  - 1432-1262 (Electronic)
IS  - 0179-1958 (Linking)
VI  - 35
IP  - 2
DP  - 2020 Feb
TI  - Regorafenib, TAS-102, or fruquintinib for metastatic colorectal cancer: any 
      difference in randomized trials?
PG  - 295-306
LID - 10.1007/s00384-019-03477-x [doi]
AB  - PURPOSE: Direct randomized comparisons of regorafenib, TAS-102, and fruquintinib 
      for treating metastatic colorectal cancer (mCRC) are lacking. Here, we evaluated 
      the efficacy and safety of three agents by a systematic review and a network 
      meta-analysis. METHODS: We included phase III randomized controlled trials in the 
      PubMed, Embase, and Scopus Cochrane databases and ClinicalTrials.gov registry 
      from initiation until January 2019. Data from randomized controlled trials 
      including overall survival (OS), progression-free survival (PFS), and adverse 
      events (AEs) were extracted. Direct meta-analysis and indirect meta-analysis 
      using network meta-analysis were assessed. RESULTS: Five trials comprising a 
      total of 2586 patients were included. For efficacy analysis of OS, no 
      statistically significant differences were observed between regorafenib and 
      TAS-102 (HR 0.945, 95% CI [0.677, 1.320], P = 0.753), regorafenib and 
      fruquintinib (HR 1.056, 95% CI [0.690, 1.621], P = 0.814), or TAS-102 and 
      fruquintinib (HR 1.117, 95% CI [0.740, 1.685], P = 0.610). However, fruquintinib 
      was superior in PFS compared with TAS-102 (HR 1.756, 95% CI [1.079, 2.857], 
      P = 0.023). Regorafenib and TAS-102 appeared to have a similar effect on PFS (HR 
      0.907, 95% CI [0.611, 1.346], P = 0.641), as did regorafenib and fruquintinib (HR 
      1.592, 95% CI [0.968, 2.618], P = 0.067). None of the three agents were better in 
      terms of all grade AEs or any grade of 3-5 AEs. However, subgroup analysis of AEs 
      exhibited different toxicity profiles between the three drugs. CONCLUSIONS: 
      Indirect comparison suggested that the three agents had similar OS but that 
      fruquintinib was superior in terms of PFS compared with that of TAS-102. These 
      three agents had different toxicity profiles.
FAU - Zhang, Qi
AU  - Zhang Q
AD  - Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and 
      Translational Research (Ministry of Education/Beijing), Peking University Cancer 
      Hospital and Institute, Beijing, 100142, China.
FAU - Wang, Qianqian
AU  - Wang Q
AD  - Department of Molecular Orthopaedics, Beijing Institute of Traumatology and 
      Orthopaedics, Beijing, 100035, China.
FAU - Wang, Xicheng
AU  - Wang X
AD  - Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and 
      Translational Research (Ministry of Education/Beijing), Peking University Cancer 
      Hospital and Institute, Beijing, 100142, China.
FAU - Li, Jian
AU  - Li J
AD  - Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and 
      Translational Research (Ministry of Education/Beijing), Peking University Cancer 
      Hospital and Institute, Beijing, 100142, China.
FAU - Shen, Lin
AU  - Shen L
AD  - Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and 
      Translational Research (Ministry of Education/Beijing), Peking University Cancer 
      Hospital and Institute, Beijing, 100142, China.
FAU - Peng, Zhi
AU  - Peng Z
AUID- ORCID: 0000-0003-4063-9813
AD  - Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and 
      Translational Research (Ministry of Education/Beijing), Peking University Cancer 
      Hospital and Institute, Beijing, 100142, China. zhipeng3@hotmail.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20191217
PL  - Germany
TA  - Int J Colorectal Dis
JT  - International journal of colorectal disease
JID - 8607899
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Benzofurans)
RN  - 0 (Drug Combinations)
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Pyridines)
RN  - 0 (Pyrrolidines)
RN  - 0 (Quinazolines)
RN  - 0 (trifluridine tipiracil drug combination)
RN  - 24T2A1DOYB (regorafenib)
RN  - 49DXG3M5ZW (HMPL-013)
RN  - 56HH86ZVCT (Uracil)
RN  - QR26YLT7LT (Thymine)
RN  - RMW9V5RW38 (Trifluridine)
SB  - IM
MH  - Antineoplastic Agents/adverse effects/*therapeutic use
MH  - Benzofurans/adverse effects/*therapeutic use
MH  - Clinical Trials, Phase III as Topic
MH  - Colorectal Neoplasms/*drug therapy/mortality/pathology
MH  - Disease Progression
MH  - Drug Combinations
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Network Meta-Analysis
MH  - Phenylurea Compounds/adverse effects/*therapeutic use
MH  - Progression-Free Survival
MH  - Pyridines/adverse effects/*therapeutic use
MH  - Pyrrolidines/adverse effects/*therapeutic use
MH  - Quinazolines/adverse effects/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Thymine
MH  - Time Factors
MH  - Trifluridine/adverse effects/*therapeutic use
MH  - Uracil/adverse effects/*analogs & derivatives/therapeutic use
OTO - NOTNLM
OT  - Fruquintinib
OT  - Meta-analysis
OT  - Refractory metastatic colorectal cancer
OT  - Regorafenib
OT  - TAS-102
EDAT- 2019/12/19 06:00
MHDA- 2020/11/18 06:00
CRDT- 2019/12/19 06:00
PHST- 2019/11/28 00:00 [accepted]
PHST- 2019/12/19 06:00 [pubmed]
PHST- 2020/11/18 06:00 [medline]
PHST- 2019/12/19 06:00 [entrez]
AID - 10.1007/s00384-019-03477-x [pii]
AID - 10.1007/s00384-019-03477-x [doi]
PST - ppublish
SO  - Int J Colorectal Dis. 2020 Feb;35(2):295-306. doi: 10.1007/s00384-019-03477-x. 
      Epub 2019 Dec 17.